Multiple myeloma after cardiac transplantation: An unusual form of posttransplant lymphoproliferative disorder

Chucrallah, Antoine; Crow, Mary K.; Rice, Lawrence; Rajagopalan, Sridharan; Hudnall, S. David

doi:10.1016/0046-8177(94)90129-5

Cited by 26 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possibility that this EBV-negative PTLD may represent a coincidental, conventional plasma cell myeloma cannot be completely excluded, although one of the 18 previously reported cases of plasma cell myeloma PTLD was also EBV negative; this EBV negative case was evaluated by both EBER in situ hybridization and polymerase chain reaction. 20 Three previously reported plasma cell myeloma PTLD were EBV positive, 21,26,33 and EBV status was not reported in the remaining 14 cases (Table 3).…”

Section: Discussionmentioning

confidence: 93%

“…23,34 Three cases showed partial response, and all were treated with chemotherapy. 10,20,26 Seven showed no response, and all but one received chemotherapy. 10,24,27,29,35,36 The one nonresponder who did not receive chemotherapy was treated with only a reduction of immunosuppression.…”

Section: Discussionmentioning

confidence: 99%

“…[23][24][25][26] The remaining four cases either lacked serum or urine monoclonal protein or bone marrow plasma cell infiltrates, or the reports did not provide these data. 10,20,27,28 At least one case 20 without a bone marrow plasma cell infiltrate had findings that were otherwise characteristic for plasma cell myeloma.…”

Section: Discussionmentioning

confidence: 99%

“…There are rare single case reports of plasma cell myeloma PTLD that meet the criteria for plasma cell myeloma as is defined in the nontransplant-related setting. 20 Most other reported cases of plasma cell myeloma PTLD, do not make a clear distinction from reactive plasmacytic hyperplasia, monomorphic, or polymorphic PTLD with plasmacytic differentiation, lesions that may also have serum monoclonal proteins.…”

mentioning

confidence: 97%

“…Plasma cell myeloma occurring after solid organ transplantation with clinical and pathologic features as defined for the nontransplant setting is rare (estimated at less than 4% of all PTLD). [17][18][19][20][21] Although most reported plasma cell myeloma PTLD cases have localized collections of plasma cells and bone marrow involvement, other clinical findings of typical plasma cell myeloma such as lytic bone lesions and hypercalcemia were frequently absent, and most were not tested for EBV. There are rare single case reports of plasma cell myeloma PTLD that meet the criteria for plasma cell myeloma as is defined in the nontransplant-related setting.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Post-transplant plasma cell myeloma and polymorphic lymphoproliferative disorder with monoclonal serum protein occurring in solid organ transplant recipients

et al. 2004

View full text Add to dashboard Cite

Post-transplant lymphoproliferative disorders are mostly Epstein-Barr virus-related, B-cell tumors that develop as a consequence of immunosuppressive therapy in recipients of solid organ or bone marrow transplants. These disorders range from reactive, polyclonal plasmacytic hyperplasia to those that are morphologically and genotypically indistinguishable from typical non-Hodgkin's lymphomas. Plasma cell myeloma occurring after solid organ transplantation is rare. We report three plasma cell myeloma post-transplant lymphoproliferative disorder cases and one polymorphic, monoclonal post-transplant lymphoproliferative disorder case associated with a monoclonal serum protein. All three plasma cell myeloma post-transplant lymphoproliferative disorder cases had clinical, radiologic, and pathologic features of conventional plasma cell myeloma. The one polymorphic post-transplant lymphoproliferative disorder case was associated with an IgM monoclonal serum protein and was morphologically indistinguishable from a lymphoplasmacytic lymphoma. Three of the four cases, including the one polymorphic post-transplant lymphoproliferative disorder case, were positive for Epstein-Barr virus encoded small RNA by in situ hybridization. One patient died of plasma cell myeloma posttransplant lymphoproliferative disorder. The remaining three patients are alive: two are completely free of posttransplant lymphoproliferative disorder, and one has shown partial response to therapy. We compare the clinicopathologic features of these cases with those in the literature.

show abstract

Section: Discussionmentioning

confidence: 93%